Martin Lehr
Founder bij CONTEXT THERAPEUTICS INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Martin A.
Lehr is the founder of Context Therapeutics LLC (founded in 2016) and Context Therapeutics, Inc. (founded in 2015), where he holds the titles of Chief Executive Officer & Director and President, Chief Executive Officer & Director, respectively.
He is currently a Director at The Biobreak Organization, Inc. (since 2009), an Independent Director at Praesidia Biotherapeutics, Inc. (since 2020), and a Board Member at CureDuchenne Ventures LLC (since 2019).
He previously worked as a Senior Associate at OUP Management Co. LLC.
Mr. Lehr received his graduate degree from The Trustees of Columbia University in The City of New York in 2009 and his undergraduate degree from the University of Pennsylvania in 2006.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-03-2024 | 979 891 ( 6.14% ) | 1 M $ | 31-03-2024 |
Actieve functies van Martin Lehr
| Bedrijven | Functie | Begin |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Founder | 01-04-2015 |
Context Therapeutics LLC
 Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Founder | 01-01-2016 |
| The Biobreak Organization, Inc. | Director/Board Member | 01-01-2009 |
Praesidia Biotherapeutics, Inc.
 Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Praesidia Biotherapeutics, Inc. is a company that specializes in developing drugs using their proprietary Tunable Linker Technology called LESS (Linker Enzyme Substrate System). The company is based in Arlington, MA. This technology helps to maximize the therapeutic potential of drugs. The company was founded by Sohang Chatterjee, Pradip K. Majumder, and Santosh Kesari, with Sohang Chatterjee serving as the CEO since incorporation. | Director/Board Member | 01-11-2020 |
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Director/Board Member | 01-05-2019 |
Eerdere bekende functies van Martin Lehr
| Bedrijven | Functie | Einde |
|---|---|---|
OUP Management Co. LLC
 OUP Management Co. LLC Investment ManagersFinance OUP Management Co. LLC (Osage Partners) is a venture capital firm founded by Robert Adelson and Louis Berneman in 1990. The firm is headquartered in Bala Cynwyd, Pennsylvania. | Private Equity Analyst | - |
Opleiding van Martin Lehr
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| University of Pennsylvania | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
OUP Management Co. LLC
OUP Management Co. LLC Investment ManagersFinance OUP Management Co. LLC (Osage Partners) is a venture capital firm founded by Robert Adelson and Louis Berneman in 1990. The firm is headquartered in Bala Cynwyd, Pennsylvania. | Finance |
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Finance |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
| Context Therapeutics, Inc. | |
| The Biobreak Organization, Inc. | |
Praesidia Biotherapeutics, Inc.
Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Praesidia Biotherapeutics, Inc. is a company that specializes in developing drugs using their proprietary Tunable Linker Technology called LESS (Linker Enzyme Substrate System). The company is based in Arlington, MA. This technology helps to maximize the therapeutic potential of drugs. The company was founded by Sohang Chatterjee, Pradip K. Majumder, and Santosh Kesari, with Sohang Chatterjee serving as the CEO since incorporation. | Health Services |
